The Department of Biotherapy, set up in 1997, is the earliest biotherapy center in China. During 20 years development, it devoted to the research and development of novel therapies, including the cutting-edge technologies and new drugs, for the comprehensive treatment of cancer patientsby combining the clinical resources of Cancer Center, West China Hospital and industrial-grade translational technology of the State Key Laboratory of Biotherapy (SKLB) of Sichuan University. All the clinical studies are meeting the international norms, and providing advanced medical care for the patients. 

Biotherapy is the most developed frontier and hot topic  in the field of cancer therapy. Immune therapy drugs such as PD-1/PD-L1 inhibitors or antibody drug conjugates have greatly improved the outcomes of patients suffering advanced cancers. Emerging bio-technologies such as CART-T or DC vaccine show promise of practice-change in the near future. The Department is committed to perform many translational studies to facilitate the transition of these new technologies and innovative biological drugs from bench to bedside. In addition, based on the characteristics of the tumor and the molecular gene condition, it provides comprehensive treatment encompassing radio- and chemo-therapy, and molecular target therapy, so as to ensure the patients with internationally upgraded treatment as soon as possible. 

The Department now has 3 professors and 4 associate professors, including 4 Ph.D. tutors and 2 master tutors. It is also equipped with full time specialists in clinical and translational studies.